...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Hepalink IPO Document and what it says about RVX

"it appears from the HL doc that a Ph3 trial on the effect of ABL on CKD might be on the cards.."

Was this determined by the chart that summarizes the development status of their pipeline drugs, found on page 9 of the IPO Summary? (Type 2 diabetes with coronary heart disease)

 

Koo

Share
New Message
Please login to post a reply